Pharma Tech

Alfasigma receives EC’s expanded approval for filgotinib to treat axSpA

Nov 6, 2026, 9:57 AM

Read Full Article → Alfasigma receives EC’s expanded approval for filgotinib to treat axSpA

Translate article text

Choose a language and wait for the translated text.

Alfasigma has received the EC's expanded approval for Jyseleca to treat adult patients living with active axial spondyloarthritis (axSpA).